Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours.

Plas, Pascale; Limana, Lorenzo; Carré, Denis; Thiongane, Amath; Raguin, Olivier; Mansi, Rosalba; Meyer-Losic, Florence; Lezmi, Stéphane

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [¹⁷⁷Lu]Lu-Satoreotide Tetraxetan and the Agonist [¹⁷⁷Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST₂-Positive Tumours.

Plas, Pascale; Limana, Lorenzo; Carré, Denis; Thiongane, Amath; Raguin, Olivier; Mansi, Rosalba; Meyer-Losic, Florence; Lezmi, Stéphane.

Afiliação

Plas P; IPSEN Innovation, 91940 Les Ulis, France.
Limana L; IPSEN Innovation, 91940 Les Ulis, France.
Carré D; IPSEN Innovation, 91940 Les Ulis, France.
Thiongane A; IPSEN Innovation, 91940 Les Ulis, France.
Raguin O; Oncodesign, 21000 Dijon, France.
Mansi R; Division of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Meyer-Losic F; IPSEN Innovation, 91940 Les Ulis, France.
Lezmi S; IPSEN Innovation, 91940 Les Ulis, France.

Pharmaceuticals (Basel) ; 15(9)2022 Aug 30.

Article em En | MEDLINE | ID: mdl-36145306

Palavras-chave

AR42J; [177Lu]Lu-DOTA-TATE; [177Lu]Lu-satoreotide tetraxetan; peptide receptor radionuclide therapy; somatostatin receptor subtype 2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article